June 24, 2025: Norway’s National Trauma Registry: Advancing Trauma Care Through Comprehensive Data

The National Trauma Registry (NTR) of Norway is a robust, population-based medical quality registry capturing detailed metadata on all seriously injured patients treated by specialist health services nationwide. With over 100 data fields, the NTR enables quality improvement in trauma care by tracking patient demographics, injury characteristics, and treatment outcomes from prehospital to rehabilitation phases.

Norwegian National Trauma Registry (Norway) **

Database Contact Data

1. Elisabeth Jeppesen
Registry Leader
Email: ntr@traumatologi.no

2. In order to apply for access to data, please send an e-mail to olav.roise@medisin.uio.no.

Alternate Contact

National Center for Traumatology
Oslo University Hospital
Ullevål, Kirkeveien 
166 0450 Oslo
NORWAY
Email: post@traumatologi.no

References of Studies Using/Describing Database

1. Nilsbakken IMW, Wisborg T, Sollid S, Jeppesen E. EMCC dispatch priority for trauma patients in Norway: a retrospective cohort study. Scand J Trauma Resusc Emerg Med. 2025 May 12;33(1):83.

2. Ringdal KG, Holm KT, Røise O. The Norwegian national trauma registry: development process and essential data insights. Scand J Trauma Resusc Emerg Med. 2025 May 1;33(1):78.

3. Aalberg I, Nordseth T, Klepstad P, Rosseland LA, Uleberg O. Incidence, severity and changes of abnormal vital signs in trauma patients: A national population-based analysis. Injury. 2025 Jan;56(1):111884.

4. Bjørke G, Dalen I, Thorsen K. Accuracy of the Norwegian trauma protocol. An observational population study from South-Western Norway. Injury. 2025 Jan;56(1):112063.

5. Sødal HF, Nordseth T, Rasmussen AJO, Rosseland LA, Stenehjem JS, Gran JM, Helseth E, Taubøll E. Risk of epilepsy after traumatic brain injury: a nationwide Norwegian matched cohort study. Front Neurol. 2024 Jun 5;15:1411692.

6. Nilsbakken I, Wisborg T, Sollid S, Jeppesen E. Functional outcome and associations with prehospital time and urban-remote disparities in trauma: A Norwegian national population-based study. Injury. 2024 Jun;55(6):111459.

7. Naberezhneva N, Uleberg O, Dahlhaug M, Giil-Jensen V, Ringdal KG, Røise O. Excellent agreement of Norwegian trauma registry data compared to corresponding data in electronic patient records. Scand J Trauma Resusc Emerg Med. 2023 Sep 26;31(1):50.

8. Dehli T, Wisborg T, Johnsen LG, Brattebø G, Eken T. Mortality after hospital admission for trauma in Norway: A retrospective observational national cohort study. Injury. 2023 Sep;54(9):110852.

9. Cuevas-Østrem M, Thorsen K, Wisborg T, Røise O, Helseth E, Jeppesen E. Care pathways and factors associated with interhospital transfer to neurotrauma centers for patients with isolated moderate-to-severe traumatic brain injury: a population-based study from the Norwegian trauma registry. Scand J Trauma Resusc Emerg Med. 2023 Jun 26;31(1):34.

10. Nilsbakken IMW, Sollid S, Wisborg T, Jeppesen E. Assessing Trauma Management in Urban and Rural Populations in Norway: A National Register-Based Research Protocol. JMIR Res Protoc. 2022 Jun 17;11(6):e30656.

June 9, 2025: New profile added from Iceland

ICEBIO is an Icelandic nationwide database on patients treated with biologic disease-modifying antirheumatic drugs (DMARDs) due to inflammatory joint diseases; including RA (rheumatoid arthritis), AS (ankylosing spondylitis), and PsA (psoriatic arthritis). The database is based on the Danish Registry for Biologic Therapies in Rheumatology, DANBIO. ICEBIO started collecting data in 2007 and contains comprehensive patient characteristics, along with disease activity scores and information on treatment.

ICEBIO (Iceland) **

Database Contact Data

Bjorn Gudbjornsson
Centre for Rheumatology Research (ICEBIO)
Landspitali University Hospital and Faculty of Medicine University of Iceland,
Reykjavik
ICELAND
Email: bjorngu@landspitali.is

Alternate Contact

N/A

References of Studies Using/Describing Database

1. Palsson O, Love TJ, Wallman JK, Kapetanovic MC, Gunnarsson PS, Gudbjornsson B. Prescription of non-steroidal anti-inflammatory drugs for patients with inflammatory arthritis decreases with the initiation of tumour necrosis factor inhibitor therapy: results from the ICEBIO registry. Scand J Rheumatol. 2024 Nov;53(6):402-408.

2. Ørnbjerg LM, Brahe CH, Linde L, Jacobsson L, Nissen MJ, Kristianslund EK, Santos MJ, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Möller B, Kvien TK, Barcelos A, Eklund KK, Tomšič M, Love TJ, Can G, Ionescu R, Loft AG, Mann H, Pavelka K, van de Sande M, van der Horst-Bruinsma IE, Suarez MP, Sánchez-Piedra C, Macfarlane GJ, Iannone F, Michelsen B, Hyldstrup LH, Krogh NS, Østergaard M, Hetland ML. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment. Joint Bone Spine. 2024 Jul;91(4):105729.

3. Linde L, Ørnbjerg LM, Heegaard Brahe C, Wallman JK, Di Giuseppe D, Závada J, Castrejon I, Díaz-Gonzalez F, Rotar Z, Tomšič M, Glintborg B, Gudbjornsson B, Geirsson AJ, Michelsen B, Kristianslund EK, Santos MJ, Barcelos A, Nordström D, Eklund KK, Ciurea A, Nissen M, Akar S, Hejl Hyldstrup L, Krogh NS, Hetland ML, Østergaard M. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching. Rheumatology (Oxford). 2024 Jul 1;63(7):1882-1892.

4. Ørnbjerg LM, Rugbjerg K, Georgiadis S, Rasmussen SH, Jacobsson L, Loft AG, Iannone F, Fagerli KM, Vencovsky J, Santos MJ, Möller B, Pombo-Suarez M, Rotar Z, Gudbjornsson B, Cefle A, Eklund K, Codreanu C, Jones G, van der Sande M, Wallman JK, Sebastiani M, Michelsen B, Závada J, Nissen MJ, Sanchez-Piedra C, Tomšič M, Love TJ, Relas H, Mogosan C, Hetland ML, Østergaard M. Patient-reported outcomes and PRO remission rates in 12,262 biologic-naïve patients with psoriatic arthritis treated with TNF-inhibitors in routine care. J Rheumatol. 2024 Jan 15:jrheum.2023-0764.

5. Glintborg B, Di Giuseppe D, Wallman JK, Nordström DC, Gudbjornsson B, Hetland ML, Askling J, Grondal G, Sokka T, Provan SA, Michelsen B, Kristianslund EK, Dreyer L, Love TJ, Lindström U. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis. 2023 Jun;82(6):820-828.

6. Nissen M, Delcoigne B, Di Giuseppe D, Jacobsson L, Hetland ML, Ciurea A, Nekvindova L, Iannone F, Akkoc N, Sokka-Isler T, Fagerli KM, Santos MJ, Codreanu C, Pombo-Suarez M, Rotar Z, Gudbjornsson B, van der Horst-Bruinsma I, Loft AG, Möller B, Mann H, Conti F, Yildirim Cetin G, Relas H, Michelsen B, Avila Ribeiro P, Ionescu R, Sanchez-Piedra C, Tomsic M, Geirsson ÁJ, Askling J, Glintborg B, Lindström U. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology (Oxford). 2022 Nov 28;61(12):4741-4751.

7. Delcoigne B, Provan SA, Hammer HB, Di Giuseppe D, Frisell T, Glintborg B, Grondal G, Gudbjornsson B, Hetland ML, Michelsen B, Nordström D, Relas H, Askling J. Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration. Rheumatology (Oxford). 2022 Nov 2;61(11):4286-4296.

8. Di Giuseppe D, Lindström U, Aaltonen K, Relas H, Provan S, Gudbjornsson B, Hetland ML, Askling J, Kauppi M, Geirsson AJ, Chatzidionysiou K, Jørgensen TS, Dreyer L, Michelsen B, Jacobsson L, Glintborg B. The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. Rheumatology (Oxford). 2022 Aug 30;61(9):3647-3656.

9. Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, Pombo-Suarez M, Mann H, Rotar Z, Eklund KK, Kvien TK, Santos MJ, Gudbjornsson B, Codreanu C, Yilmaz S, Wallman JK, Brahe CH, Möller B, Favalli EG, Sánchez-Piedra C, Nekvindova L, Tomsic M, Trokovic N, Kristianslund EK, Santos H, Löve TJ, Ionescu R, Pehlivan Y, Jones GT, van der Horst-Bruinsma I, Ørnbjerg LM, Østergaard M, Hetland ML. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care Res (Hoboken). 2022 Jul;74(7):1205-1218.

10. Glintborg B, Lindström U, Giuseppe DD, Provan SA, Gudbjornsson B, Hetland ML, Michelsen B, Wallman JK, Aaltonen K, Hokkanen AM, Nordström D, Jørgensen TS, Hansen RL, Geirsson AJ, Grøn KL, Krogh NS, Askling J, Kristensen LE, Jacobsson LTH; Danish Rheumatology Database (DANBIO), Anti-Rheumatic Therapy in Sweden/Swedish Rheumatology Quality (ARTIS/SRQ), Center for Rheumatology Research (ICEBIO), Finnish Register of Biological Treatment (ROB-FIN), and Norwegian Antirheumatic Drug Register (NOR-DMARD) registries. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses. Arthritis Care Res (Hoboken). 2022 May;74(5):748-758. 

May 27, 2025: Information on the National Adult Cardiac Surgery Audit (NACSA) is now available

With data starting in 1977, NACSA is the primary database for collecting data on adult cardiac surgery in the United Kingdom, including information from NHS and private hospitals. This audit, part of the National Cardiac Audit Programme (NCAP), provides an overview of the state of cardiac surgery in the UK, including activity trends and quality measures.

Subscribe to